Search Result

Pathways Recommended:	Anti-infection

Results for "

SARS-CoV infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (111) AAK1 (2) Akt (2) Angiotensin-converting Enzyme (ACE) (5) Antibiotic (11) Apoptosis (9) Autophagy (20) Bacterial (8) Cathepsin (2) CDK (1) DNA/RNA Synthesis (8) Drug Metabolite (3) EGFR (1) Endogenous Metabolite (7) ERK (1) Fluorescent Dye (1) FXR (4) G protein-coupled Bile Acid Receptor 1 (2) Glycosidase (1) HBV (1) HCV (3) HDAC (1) Histamine Receptor (1) Histone Methyltransferase (1) HIV (28) HIV Protease (11) Influenza Virus (2) Isotope-Labeled Compounds (14) MDM-2/p53 (1) Microtubule/Tubulin (1) MMP (1) PAI-1 (1) Parasite (17) PKC (1) Reference Standards (1) Ser/Thr Protease (6) Toll-like Receptor (TLR) (18) VEGFR (2) Virus Protease (9)
By Research Areas:	Cancer (36) Cardiovascular Disease (4) Infection (109) Inflammation/Immunology (13) Metabolic Disease (11) Neurological Disease (3)

By Targets:

SARS-CoV (111)

AAK1 (2)

Akt (2)

Angiotensin-converting Enzyme (ACE) (5)

Antibiotic (11)

Apoptosis (9)

Autophagy (20)

Bacterial (8)

Cathepsin (2)

CDK (1)

DNA/RNA Synthesis (8)

Drug Metabolite (3)

EGFR (1)

Endogenous Metabolite (7)

ERK (1)

Fluorescent Dye (1)

FXR (4)

G protein-coupled Bile Acid Receptor 1 (2)

Glycosidase (1)

HBV (1)

HCV (3)

HDAC (1)

Histamine Receptor (1)

Histone Methyltransferase (1)

HIV (28)

HIV Protease (11)

Influenza Virus (2)

Isotope-Labeled Compounds (14)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

MMP (1)

PAI-1 (1)

Parasite (17)

PKC (1)

Reference Standards (1)

Ser/Thr Protease (6)

Toll-like Receptor (TLR) (18)

VEGFR (2)

Virus Protease (9)

By Research Areas:

Cancer (36)

Cardiovascular Disease (4)

Infection (109)

Inflammation/Immunology (13)

Metabolic Disease (11)

Neurological Disease (3)

123

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156651

Zevotrelvir EDP-235	SARS-CoV	Infection
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC₅₀ ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections .

HY-129116

SSAA09E1	SARS-CoV Cathepsin	Infection
SSAA09E1 is a cathepsin L blocker (IC₅₀: 5.33 μM).SSAA09E1 inhibits stages of viral entry. SSAA09E1 can be used for SARS-CoV infection research

HY-104077

Remdesivir 170+ Cited Publications GS-5734	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-171189

C-467929	SARS-CoV	Infection
C-467929 is an Nsp15 endoribonuclease inhibitor with an IC₅₀ of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research .

HY-104077A

Remdesivir maleate GS-5734 maleate	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir maleate, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir maleate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-104077R

Remdesivir (Standard)	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (Standard) is the analytical standard of Remdesivir. This product is intended for research and analytical applications. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-136606

SARS-CoV MPro-IN-1	SARS-CoV	Infection
SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC₅₀ of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC₅₀ of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .

HY-162604

SARS-CoV-2-IN-90	SARS-CoV	Infection
SARS-CoV-2-IN-90 (compound 3i) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .

HY-163713

SARS-CoV-2-IN-89	SARS-CoV	Infection
SARS-CoV-2-IN-89 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of *SARS-CoV-2* infection .

HY-172760

CIM-834	Virus Protease SARS-CoV	Infection
CIM-834 is an orally active and selective inhibitor targeting the coronavirus membrane protein (M protein), which potently blocks viral assembly against *SARS-CoV-2* and *SARS-CoV. CIM-834 binds to the short form of the M protein (M_short) in a non-covalent manner, stabilizing M_short and preventing its conformational switch to the long form (M_long) required for virion assembly, thereby inhibiting viral particle formation. CIM-834 is promising for research of COVID-19 and other coronavirus infections* .

HY-146379

SARS-CoV-2-IN-19	SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-104077S

Remdesivir-d5 2 Publications Verification GS-5734-d₅	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro .

HY-170767

SARS-CoV-2-IN-109	SARS-CoV	Infection
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting *SARS-CoV* with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC₅₀=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC₅₀=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .

HY-161261

SARS-CoV-2-IN-81	AAK1 SARS-CoV	Infection
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC₅₀ value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against *SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection* .

HY-157305

Jun11165	SARS-CoV	Infection
Jun11165 is a SARS-CoV-2 PL ^pro inhibitor (IC₅₀ ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC₅₀ value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .

HY-138102

SSAA09E3	SARS-CoV	Infection
SSAA09E3 is a *SARS-CoV* entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC₅₀ of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC₅₀ of 0.15 μM .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Bacterial Antibiotic	Infection
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Antibiotic HIV SARS-CoV	Infection
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-153228

Pomotrelvir PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-168441

NCGC00537446	SARS-CoV	Infection
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .

HY-169092

PF-07957472	SARS-CoV Virus Protease	Infection
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC₅₀ = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection* and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-145949

Remdesivir de(ethylbutyl 2-aminopropanoate)	Drug Metabolite	Infection
Remdesivir de(ethylbutyl 2-aminopropanoate) is an impurity of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M ^pro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of *SARS-CoV-2* and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-104077S1

Remdesivir-d4 GS-5734-d₄	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-156597

Arbemnifosbuvir AT-752 free base	SARS-CoV	Infection
Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .

HY-104077S2

Remdesivir impurity 9-d4	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-161844

Virapinib	SARS-CoV	Infection
Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by *SARS-CoV-2, as well as by additional viruses, such as mpox virus* and TBEV .

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-19727A

FOY 251 2 Publications Verification	Ser/Thr Protease SARS-CoV	Metabolic Disease
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-173521

JNJ-9676	SARS-CoV DNA/RNA Synthesis	Infection
JNJ-9676 is an orally active inhibitor of membrane (M) protein. JNJ-9676 has in vitro antiviral activity against SARS-CoV-2, SARS-CoV, and sarbecovirus from bats and pangolins. JNJ-9676 inhibits viral assembly by stabilizing the conformational changes of the M protein dimer, preventing the release of infectious viruses. JNJ-9676 has significant antiviral effects and can be used in research on the prevention and treatment of coronavirus infections .

HY-19727

FOY 251 free base	Ser/Thr Protease SARS-CoV	Infection Metabolic Disease
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor . FOY 25 free base inhibits SARS-CoV-2 infection in cells assay .

HY-136597

Remdesivir O-desphosphate acetonide impurity 2 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-171160

WYFA-15	SARS-CoV	Infection
WYFA-15 is a sphingomyelin synthase 1 (SMS1) inhibitor that protects mice against lethal SFTSV infection and reduce *SARS-CoV-2* replication and pathogenesis. WYFA-15 can be utilized in anti-virus research .

HY-144798

FWM-5	SARS-CoV	Infection
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .

HY-90001S

Ritonavir-d6 ABT 538-d₆; RTV-d₆	HIV Protease HIV SARS-CoV Apoptosis	Infection
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-170504

ZHAWOC25153	SARS-CoV Virus Protease	Infection
ZHAWOC25153 (Compound 17o) is a SARS-CoV-2 papain-like cysteine protease (PLpro) inhibitor, with an IC₅₀ of 7 μM. ZHAWOC25153 exhibits antiviral activity and can be used in research within the field of anti-infection .

HY-W653853

Ritonavir-13C3 ABT 538-¹³C₃; RTV-¹³C₃	Isotope-Labeled Compounds Apoptosis SARS-CoV HIV Protease HIV	Cancer
Ritonavir- ¹³C₃ is ¹³C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM .

Cat. No.	Product Name

HY-L002

Anti-Infection Compound Library

3,466 compounds

An infection occurs when another organism enters a person’s body and causes disease. The organisms that cause infections are very diverse and can include things like viruses, bacteria, fungi, and parasites. The immune system is an effective barrier against infectious agents.

MCE provides a unique collection of 3,466 anti-infective compounds with anti-bacterial, anti-viral, anti-fungal and anti-parasite activities that can be used for drug screening and other research in anti-microbial area.

HY-L027

Antiviral Compound Library

1,410 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1,410 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-P2296

Abz-FRLKGGAPIKGV-EDDNP TFA	Fluorescent Dye	Others
Abz-FRLKGGAPIKGV-EDDNP TFA is a fluorogenic substrate used to measure the enzymatic activities of protease forms, such as papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV). Abz-FRLKGGAPIKGV-EDDNP TFA has the potential for study 2019-nCoV (COVID-19) infection .

Cat. No.	Product Name	Target	Research Area

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Structural Classification Microorganisms Source classification Polyphenols Disease Research Fields	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-N10109A

Gallinamide A TFA	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-126419

Kobophenol A	Infection Classification of Application Fields Source classification Cyperaceae Phenols Polyphenols Plants Disease Research Fields Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-110066

(Z)-Guggulsterone 5 Publications Verification	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-B1513

α-Cyclodextrin 2 Publications Verification	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	Microtubule/Tubulin SARS-CoV
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 16 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing *SARS-CoV-2* infection. Orally active .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-W399297R

Isodeoxycholic acid (Standard)	Structural Classification Source classification Endogenous metabolite Steroids	Endogenous Metabolite
Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-N14351

Ferrocin A	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Bacterial Antibiotic
Ferrocin A is a lipopeptide compound that targets the *SARS-CoV-2* RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .

HY-110066R

(Z)-Guggulsterone (Standard)	Structural Classification Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Steroids	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-13771R

Ursodeoxycholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-W012531

2-Hydroxycinnamic acid	Infection Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae Disease Research Fields	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-W012531R

2-Hydroxycinnamic acid (Standard)	Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of *HIV/SARS-CoV* S pseudovirus with an IC₅₀** of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-B1624A

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields	Endogenous Metabolite
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

Cat. No.	Product Name	Chemical Structure

HY-104077S

Remdesivir-d5 2 Publications Verification
Remdesivir-d₅ is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC₅₀s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro .

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-W653853

Ritonavir-13C3
Ritonavir- ¹³C₃ is ¹³C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM .

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-90001S2

Ritonavir-d8
Ritonavir-d₈ is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.09 μM .

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-17430S2

Amprenavir-13C6
Amprenavir- ¹³C₆ (VX-478- ¹³C₆) is ¹³C labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆) is the deuterium labeled rel-Ritonavir. rel-Ritonavir is a relative configuration of Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to study of HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-W012531S2

2-Hydroxycinnamic acid-d4

2-Hydroxycinnamic acid-d₄ is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

Cat. No.	Product Name		Classification